JUDICIAL PANEL ON MULTIDISTRICT LITIGATION

JUN 3 0 2005

FILED CLERK'S OFFICE



DOCKET NO. 1456

BEFORE THE JUDICIAL PANEL ON MULTIDISTRICT LITIGATION

IN RE PHARMACEUTICAL INDUSTRY AVERAGE WHOLESALE PRICE LITIGATION

The County of Niagara v. Abbott Laboratories, Inc., et al., W.D. New York, C.A. No. 6:05-6296

CONDITIONAL TRANSFER ORDER (CTO-23)

On April 30, 2002, the Panel transferred 16 civil actions to the United States District Court for the District of Massachusetts for coordinated or consolidated pretrial proceedings pursuant to 28 U.S.C. § 1407. Since that time, 58 additional actions have been transferred to the District of Massachusetts. With the consent of that court, all such actions have been assigned to the Honorable Patti B. Saris.

It appears that the action on this conditional transfer order involves questions of fact which are common to the actions previously transferred to the District of Massachusetts and assigned to Judge Saris.

Pursuant to Rule 7.4 of the Rules of Procedure of the Judicial Panel on Multidistrict Litigation, 199 F.R.D. 425, 435-36 (2001), this action is transferred under 28 U.S.C. § 1407 to the District of Massachusetts for the reasons stated in the order of April 30, 2002, 201 F.Supp.2d 1378 (J.P.M.L. 2002), and, with the consent of that court, assigned to the Honorable Patti B. Saris.

This order does not become effective until it is filed in the Office of the Clerk of the United States District Court for the District of Massachusetts. The transmittal of this order to said Clerk shall be stayed fifteen (15) days from the entry thereof and if any party files a notice of opposition with the Clerk of the Panel within this fifteen (15) day period, the stay will be continued until further order of the Panel.

FOR THE PANEL:

Inasmuch as no objection is pending at this time, the stay is lifted.

JUL 18 2005

CLERK'S OFFICE JUDICIAL PANEL ON MULTIDISTRICT LITIGATION Clerk of the Panel

MWP

U.S. DISTRICT COURT WESTERN DISTRICT OF NEW YORK [LIVE] (Rochester) CIVIL DOCKET FOR CASE #: 6:05-cv-06296-MAT

County of Niagara v. Abbott Laboratories, Inc. et al

Assigned to: Hon. Michael A. Telesca

Cause: 28:1331 Fed. Question: Breach of Contract

Date Filed: 06/08/2005 Jury Demand: Plaintiff

Nature of Suit: 890 Other Statutory

Actions

Jurisdiction: Federal Question

Plaintiff

The County of Niagara

represented by Aaron D. Hovan

Kirby McInerney & Squire, LLP

830 Third Avenue

Suite 10

New York, NY 10022

212-371-6600

Fax: 212-751-2540

Email: ahovan@kmslaw.com

LEAD ATTORNEY

ATTORNEY TO BE NOTICED

Joanne M. Cicala

Kirby McInerney & Squire, LLP

830 Third Avenue

Suite 10

New York, NY 10022

212-371-6600

Fax: 212-751-2540

Email: jcicala@kmslaw.com

LEAD ATTORNEY

ATTORNEY TO BE NOTICED

V.

Defendant

Abbott Laboratories, Inc.


Defendant


Agouron Pharmaceuticals, Inc.

Defendant

Alcon Laboratories, Inc.

Defendant Alpharma, Inc. Defendant Amgen, Inc. Defendant Andrx Corp. Defendant AstraZeneca Pharmaceuticals L.P. Defendant Aventis Pharmaceuticals, Inc. Defendant Barr Laboratories, Inc. Defendant Bayer Corp. Defendant Ben Venue Laboratories, Inc. Defendant Berlex Laboratories, Inc. Defendant Borlex Laboratories, Inc. Defendant Borlex Laboratories, Inc. Defendant Borley Inc. Defendant Biogen Idee, Inc. Defendant Biovail Pharmaceuticals, Inc. Defendant Boohringer Ingelheim Corp. Defendant Boohringer Ingelheim Pharmaceuticals, Inc. Defendant Boohringer Ingelheim Pharmaceuticals, Inc. Defendant Boohringer Squibb Company	Allergan	, Inc.		
Defendant Amgen, Inc. Defendant Andrx Corp. Defendant AstraZeneca Pharmaceuticals L.P. Defendant Aventis Pharmaceuticals, Inc. Defendant Barr Laboratories, Inc. Defendant Bayer Corp. Defendant Ben Venue Laboratories, Inc. Defendant Berlex Laboratories, Inc. Defendant Berlex Laboratories, Inc. Defendant Borlex Laboratories, Inc. Defendant Bookringer Ingelheim Corp. Defendant Bookringer Ingelheim Pharmaceuticals, Inc. Defendant Bookringer Ingelheim Pharmaceuticals, Inc.	Defenda	<u>nt</u>		
Amgen, Inc. Defendant Andrx Corp. Defendant AstraZeneca Pharmaceuticals L.P. Defendant Aventis Pharmaceuticals, Inc. Defendant Barr Laboratories, Inc. Defendant Bayer Corp. Defendant Ben Venue Laboratories, Inc. Defendant Berlex Laboratories, Inc. Defendant Biogen Idec, Inc. Defendant Biogen Idec, Inc. Defendant Biowail Pharmaceuticals, Inc. Defendant Boehringer Ingelheim Corp. Defendant Boehringer Ingelheim Pharmaceuticals, Inc. Defendant Boehringer Ingelheim Pharmaceuticals, Inc.	Alpharm	a, Inc.		
Defendant Andrx Corp. Defendant AstraZeneca Pharmaceuticals L.P. Defendant Aventis Pharmaceuticals, Inc. Defendant Barr Laboratories, Inc. Defendant Bayer Corp. Defendant Ben Venue Laboratories, Inc. Defendant Berlex Laboratories, Inc. Defendant Biogen Idec, Inc. Defendant Biogen Idec, Inc. Defendant Biovail Pharmaceuticals, Inc. Defendant Boehringer Ingelheim Corp. Defendant Boehringer Ingelheim Pharmaceuticals, Inc. Defendant Boehringer Ingelheim Pharmaceuticals, Inc.	<u>Defenda</u>	<u>nt</u>		
Andrx Corp. Defendant AstraZeneca Pharmaceuticals L.P. Defendant Aventis Pharmaceuticals, Inc. Defendant Barr Laboratories, Inc. Defendant Bayer Corp. Defendant Ben Venue Laboratories, Inc. Defendant Berlex Laboratories, Inc. Defendant Biogen Idec, Inc. Defendant Biovail Pharmaceuticals, Inc. Defendant Boehringer Ingelheim Corp. Defendant Boehringer Ingelheim Pharmaceuticals, Inc. Defendant Boehringer Ingelheim Pharmaceuticals, Inc.	Amgen,	Inc.		
Defendant AstraZeneca Pharmaceuticals L.P. Defendant Aventis Pharmaceuticals, Inc. Defendant Barr Laboratories, Inc. Defendant Bayer Corp. Defendant Ben Venue Laboratories, Inc. Defendant Berlex Laboratories, Inc. Defendant Biogen Idec, Inc. Defendant Biovail Pharmaceuticals, Inc. Defendant Bochringer Ingelheim Corp. Defendant Bochringer Ingelheim Pharmaceuticals, Inc.	Defenda	<u>nt</u>		
AstraZeneca Pharmaceuticals L.P. Defendant Aventis Pharmaceuticals, Inc. Defendant Barr Laboratories, Inc. Defendant Bayer Corp. Defendant Ben Venue Laboratories, Inc. Defendant Berlex Laboratories, Inc. Defendant Biogen Idec, Inc. Defendant Biovail Pharmaceuticals, Inc. Defendant Boehringer Ingelheim Corp. Defendant Boehringer Ingelheim Pharmaceuticals, Inc.	Andrx C	orp.		
Defendant Barr Laboratories, Inc. Defendant Bayer Corp. Defendant Ben Venue Laboratories, Inc. Defendant Berlex Laboratories, Inc. Defendant Biogen Idec, Inc. Defendant Biovail Pharmaceuticals, Inc. Defendant Boehringer Ingelheim Corp. Defendant Boehringer Ingelheim Pharmaceuticals, Inc.	Defenda	<u>nt</u>		
Aventis Pharmaceuticals, Inc. Defendant Barr Laboratories, Inc. Defendant Bayer Corp. Defendant Ben Venue Laboratories, Inc. Defendant Berlex Laboratories, Inc. Defendant Biogen Idec, Inc. Defendant Biovail Pharmaceuticals, Inc. Defendant Boehringer Ingelheim Corp. Defendant Boehringer Ingelheim Pharmaceuticals, Inc. Defendant Boehringer Ingelheim Pharmaceuticals, Inc.	AstraZei	neca Pharmaceuticals L.P.		
Defendant Bayer Corp. Defendant Ben Venue Laboratories, Inc. Defendant Berlex Laboratories, Inc. Defendant Biogen Idec, Inc. Defendant Biovail Pharmaceuticals, Inc. Defendant Boehringer Ingelheim Corp. Defendant Boehringer Ingelheim Pharmaceuticals, Inc.	Defenda	<u>1t</u>		
Barr Laboratories, Inc. Defendant Bayer Corp. Defendant Ben Venue Laboratories, Inc. Defendant Berlex Laboratories, Inc. Defendant Biogen Idec, Inc. Defendant Biovail Pharmaceuticals, Inc. Defendant Boehringer Ingelheim Corp. Defendant Boehringer Ingelheim Pharmaceuticals, Inc.	Aventis 1	Pharmaceuticals, Inc.		
Defendant Bayer Corp. Defendant Ben Venue Laboratories, Inc. Defendant Berlex Laboratories, Inc. Defendant Biogen Idec, Inc. Defendant Biovail Pharmaceuticals, Inc. Defendant Boehringer Ingelheim Corp. Defendant Boehringer Ingelheim Pharmaceuticals, Inc.	<u>Defenda</u>	<u>nt</u>		
Bayer Corp. Defendant Ben Venue Laboratories, Inc. Defendant Berlex Laboratories, Inc. Defendant Biogen Idec, Inc. Defendant Biovail Pharmaceuticals, Inc. Defendant Boehringer Ingelheim Corp. Defendant Boehringer Ingelheim Pharmaceuticals, Inc.	Barr Lal	ooratories, Inc.		
Defendant Ben Venue Laboratories, Inc. Defendant Berlex Laboratories, Inc. Defendant Biogen Idec, Inc. Defendant Biovail Pharmaceuticals, Inc. Defendant Boehringer Ingelheim Corp. Defendant Boehringer Ingelheim Pharmaceuticals, Inc.	Defenda	<u>1t</u>		
Ben Venue Laboratories, Inc. Defendant Berlex Laboratories, Inc. Defendant Biogen Idec, Inc. Defendant Biovail Pharmaceuticals, Inc. Defendant Boehringer Ingelheim Corp. Defendant Boehringer Ingelheim Pharmaceuticals, Inc.	Bayer Co	orp.		
Defendant Berlex Laboratories, Inc. Defendant Biogen Idec, Inc. Defendant Biovail Pharmaceuticals, Inc. Defendant Boehringer Ingelheim Corp. Defendant Boehringer Ingelheim Pharmaceuticals, Inc. Defendant Boehringer Ingelheim Pharmaceuticals, Inc.	Defenda	<u>1t</u>		
Berlex Laboratories, Inc. Defendant Biogen Idec, Inc. Defendant Biovail Pharmaceuticals, Inc. Defendant Boehringer Ingelheim Corp. Defendant Boehringer Ingelheim Pharmaceuticals, Inc. Defendant Boehringer Ingelheim Pharmaceuticals, Inc.	Ben Ven	ue Laboratories, Inc.		
Defendant Biogen Idec, Inc. Defendant Biovail Pharmaceuticals, Inc. Defendant Boehringer Ingelheim Corp. Defendant Boehringer Ingelheim Pharmaceuticals, Inc. Defendant Defendant Defendant Defendant	Defenda	<u>1t</u>		
Biogen Idec, Inc. Defendant Biovail Pharmaceuticals, Inc. Defendant Boehringer Ingelheim Corp. Defendant Boehringer Ingelheim Pharmaceuticals, Inc. Defendant	Berlex L	aboratories, Inc.		
Defendant Biovail Pharmaceuticals, Inc. Defendant Boehringer Ingelheim Corp. Defendant Boehringer Ingelheim Pharmaceuticals, Inc. Defendant	<u>Defendar</u>	<u>1t</u>		
Biovail Pharmaceuticals, Inc. Defendant Boehringer Ingelheim Corp. Defendant Boehringer Ingelheim Pharmaceuticals, Inc. Defendant	Biogen I	dec, Inc.		
Defendant Boehringer Ingelheim Corp. Defendant Boehringer Ingelheim Pharmaceuticals, Inc. Defendant	Defenda	<u>1t</u>		
Boehringer Ingelheim Corp. Defendant Boehringer Ingelheim Pharmaceuticals, Inc. Defendant	Biovail P	harmaceuticals, Inc.		
Defendant Boehringer Ingelheim Pharmaceuticals, Inc. Defendant	Defenda	<u>1t</u>		
Boehringer Ingelheim Pharmaceuticals, Inc. Defendant	Boehring	er Ingelheim Corp.		
Pharmaceuticals, Inc. Defendant	Defenda	<u>ıt</u>		
Bristol-Meyers Squibb Company	<u>Defendar</u>	<u>ıt</u>		
	Bristol-M	leyers Squibb Company		





Monarch Pharmaceuticals, Inc.

Defendant

Mylan Laboratories, Inc.

Defendant

Mylan Pharmaceuticals, Inc.

Defendant

Novartis Pharmaceuticals Corp.

Defendant

Novo Nordisk Pharmaceuticals, Inc.

Oncology Therapeutics Network

Corp.

Defendant

Organon Pharmaceuticals USA, Inc.

Defendant

Ortho Biotech Products, LP

Defendant

Ortho-McNeil Pharmaceutical, Inc.

Defendant

Par Pharmaceutical, Inc.

Defendant

Pfizer, Inc.

Defendant

Pharmacia Corp.

Defendant

Purdue Pharma, L.P.

Defendant

Purepac Pharmaceutical Co.

Defendant

Reliant Pharmaceuticals

Defendant

Roche Laboratories, Inc.

Defendant

Roxane Laboratories, Inc.

Defendant

Sandoz, Inc.

Defendant

Sanofi-Synthelabo, Inc.

Defendant

Schering Corp.

Schering-Plough Corp.

Defendant

Serono, Inc.

Defendant

SmithKlineBeecham Corp. d/b/a GlaxoSmithKline

Defendant

Takeda Pharmaceuticals North America, Inc.

Defendant

Tap Pharmaceutical Products, Inc.

Defendant

Teva Pharmaceutical USA, Inc.

Defendant

UCB Pharma, Inc.

Defendant

UDL Laboratories, Inc.

Defendant

Warrick Pharmaceuticals Corp.

Defendant

Watson Pharma, Inc.

Defendant

Watson Pharmaceuticals, Inc.

Defendant

Wyeth

Date Filed	#	Docket Text	
06/08/2005	1	COMPLAINT against all defendants (Filing fee \$250 receipt number 67751), filed by The County of Niagara. (Attachments: # 1 Exhibit A; # 2 Exhibit B; # 3 Exhibit C; # 4 Exhibit D; and, # 5 Exhibit E)(JHF) (Entered: 06/09/2005)	

06/08/2005 Summons Issued as to all defendants. (JHF) (Entered: 06/09/2005)

	PACE	R Service C	'enter				
Transaction Receipt							
07/27/2005 17:08:38							
PACER Login:	us2510	Client Code	:				
Description:	Docket Report	Search Criteria:	6:05-cv-06296-MAT				
Billable Pages:	,3	Cost:	0.24				